Inhibition of Human Papillomavirus Expression Using DNAzymes

6Citations
Citations of this article
7Readers
Mendeley users who have this article in their library.
Get full text

Abstract

Deoxyribozymes (DXZs) are catalytic oligodeoxynucleotides capable of performing diverse functions including the specific cleavage of a target RNA. These molecules represent a new type of therapeutic oligonucleotides combining the efficiency of ribozymes and the intracellular endurance and simplicity of modified antisense oligonucleotides. Commonly used DXZs include the 8–17 and 10–23 motifs, which have been engineered to destroy disease-associated genes with remarkable efficiency. Targeting DXZs to disease-associated transcripts requires extensive biochemical testing to establish target RNA accessibility, catalytic efficiency, and nuclease sensibility. The usage of modified nucleotides to render nuclease-resistance DXZs must be counterweighted against deleterious consequences on catalytic activity. Further intracellular testing is required to establish the effect of microenvironmental conditions on DXZ activity and off-target issues. Application of modified DXZs to cervical cancer results in specific growth inhibition, cell death, and apoptosis. Thus, DXZs represent a highly effective antisense moiety with minimal secondary effects.

Cite

CITATION STYLE

APA

Benítez-Hess, M. L., Reyes-Gutiérrez, P., & Alvarez-Salas, L. M. (2011). Inhibition of Human Papillomavirus Expression Using DNAzymes. In Methods in Molecular Biology (Vol. 764, pp. 317–335). Humana Press Inc. https://doi.org/10.1007/978-1-61779-188-8_21

Register to see more suggestions

Mendeley helps you to discover research relevant for your work.

Already have an account?

Save time finding and organizing research with Mendeley

Sign up for free